IL155817A0 - Combination therapy for estrogen-dependent disorders - Google Patents

Combination therapy for estrogen-dependent disorders

Info

Publication number
IL155817A0
IL155817A0 IL15581701A IL15581701A IL155817A0 IL 155817 A0 IL155817 A0 IL 155817A0 IL 15581701 A IL15581701 A IL 15581701A IL 15581701 A IL15581701 A IL 15581701A IL 155817 A0 IL155817 A0 IL 155817A0
Authority
IL
Israel
Prior art keywords
estrogen
combination therapy
dependent disorders
disorders
dependent
Prior art date
Application number
IL15581701A
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL155817A0 publication Critical patent/IL155817A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15581701A 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders IL155817A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71460500A 2000-11-16 2000-11-16
PCT/US2001/043847 WO2002039995A2 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders

Publications (1)

Publication Number Publication Date
IL155817A0 true IL155817A0 (en) 2003-12-23

Family

ID=24870727

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15581701A IL155817A0 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders

Country Status (16)

Country Link
EP (1) EP1341549A2 (en)
JP (1) JP2004536022A (en)
KR (1) KR20030051828A (en)
CN (1) CN1498112A (en)
AU (1) AU2002230464A1 (en)
BR (1) BR0115423A (en)
CA (1) CA2428249A1 (en)
CZ (1) CZ20031349A3 (en)
EA (1) EA200300572A1 (en)
IL (1) IL155817A0 (en)
MX (1) MXPA03004195A (en)
NO (1) NO20032206L (en)
NZ (1) NZ525720A (en)
PL (1) PL365904A1 (en)
WO (1) WO2002039995A2 (en)
ZA (1) ZA200303669B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2148682A1 (en) * 2007-04-23 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
CN101775054B (en) * 2010-02-05 2012-12-26 常州佳尔科药业集团有限公司 Synthesis method of 4-hydroxyl-4-alkene-3-ketone steroide compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
PL365904A1 (en) 2005-01-10
CZ20031349A3 (en) 2004-05-12
ZA200303669B (en) 2004-05-13
KR20030051828A (en) 2003-06-25
BR0115423A (en) 2005-12-13
WO2002039995A3 (en) 2003-05-01
EA200300572A1 (en) 2004-06-24
JP2004536022A (en) 2004-12-02
AU2002230464A1 (en) 2002-05-27
CA2428249A1 (en) 2002-05-23
MXPA03004195A (en) 2003-09-22
WO2002039995A9 (en) 2003-02-06
NZ525720A (en) 2006-12-22
CN1498112A (en) 2004-05-19
WO2002039995A2 (en) 2002-05-23
EP1341549A2 (en) 2003-09-10
NO20032206D0 (en) 2003-05-15
NO20032206L (en) 2003-07-15

Similar Documents

Publication Publication Date Title
GB0012671D0 (en) Therapeutic agents
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
GB0018473D0 (en) Therapeutic agents
EP1296697A4 (en) Therapeutic agents - i
GB0009606D0 (en) Therapeutic combinations
GB0017256D0 (en) Therapeutic agents
GB0028429D0 (en) Therapy
GB0027561D0 (en) Therapeutic agents
GB0005789D0 (en) Therapeutic agents
GB0007907D0 (en) Therapeutic agents
GB0012214D0 (en) Therapeutic agents
GB0008696D0 (en) Therapeutic agents
GB0023610D0 (en) Therapeutic agents
GB0000564D0 (en) Therapeutic agents
GB0020721D0 (en) Therapeutic agents
GB0017518D0 (en) Therapeutic agents
IL155817A0 (en) Combination therapy for estrogen-dependent disorders
GB0007376D0 (en) Therapeutic agents
GB0017543D0 (en) Therapeutic agents
GB0022988D0 (en) Therapeutic agents
GB0014135D0 (en) Combination therapy
GB0013927D0 (en) Combination therapy
GB0014137D0 (en) Combination therapy
GB0007740D0 (en) Combination therapy